Literature DB >> 2750480

In vivo CNS demyelination mediated by anti-galactocerebroside antibody.

K Ozawa1, T Saida, K Saida, H Nishitani, M Kameyama.   

Abstract

The mechanism of antibody-mediated central nervous system (CNS) demyelination in vivo was studied using rabbit eyes. Injection of anti-galactocerebroside (Gal C) antiserum alone into the normal rabbit vitreous body induced demyelination in the epiretinal myelinated fibers. This activity of the antiserum disappeared after heat treatment at 56 degrees C for 30 min and was restored by supplement of normal fresh serum, suggesting the complement dependency of the activity. Heated anti-Gal C antiserum could induce demyelination, however, when macrophages were introduced by injecting lymphocyte supernatants together with antiserum. Electron microscopic study revealed penetration of macrophage process between the myelin lamella. These findings suggest that the cooperation of anti-Gal C antibody and macrophage can result in the antibody-dependent cell-mediated demyelination in the absence of complement. Because oligodendrocyte generally appeared normal, myelin, not oligodendrocyte is suspected to be the primary target by anti-Gal C antiserum. In contrast, neither anti-MBP nor anti-gangliosides antiserum had the in vivo-demyelinating activity. In CNS demyelination by anti-Gal C antibody, complement-mediated and macrophage-mediated mechanisms may cooperate in varying degrees.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2750480     DOI: 10.1007/bf00687890

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  47 in total

1.  Experimental allergic encephalomyelitis: an ultrastructural study of experimental demyelination in vitro.

Authors:  C S Raine; M B Bornstein
Journal:  J Neuropathol Exp Neurol       Date:  1970-04       Impact factor: 3.685

2.  Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis.

Authors:  L G Epstein; J W Prineas; C S Raine
Journal:  J Neurol Sci       Date:  1983 Oct-Nov       Impact factor: 3.181

3.  Myelin-binding antibodies in vitro. Immunoperoxidase studies with experimental allergic encephalomyelitis, anti-galactocerebroside and multiple sclerosis sera.

Authors:  A B Johnson; M B Bornstein
Journal:  Brain Res       Date:  1978-12-22       Impact factor: 3.252

4.  Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides.

Authors:  Y Nagai; T Momoi; M Saito; E Mitsuzawa; S Ohtani
Journal:  Neurosci Lett       Date:  1976-04       Impact factor: 3.046

5.  Studies on autoimmune encephalomyelitis in the guinea pig. II. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor.

Authors:  R Lebar; J M Boutry; C Vincent; R Robineaux; G A Voisin
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

6.  In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis. Antibody nature of the demyelinating factor and the role of complement.

Authors:  H Lassmann; H Stemberger; K Kitz; H M Wisniewski
Journal:  J Neurol Sci       Date:  1983-04       Impact factor: 3.181

7.  Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion.

Authors:  C S Raine; L Scheinberg; J M Waltz
Journal:  Lab Invest       Date:  1981-12       Impact factor: 5.662

8.  Cerebroside antibody inhibits sulfatide synthesis and myelination and demyelinates in cord tissue cultures.

Authors:  J M Fry; S Weissbarth; G M Lehrer; M B Bornstein
Journal:  Science       Date:  1974-02-08       Impact factor: 47.728

9.  Antigalactocerebroside serum demyelinates optic nerve in vivo.

Authors:  R C Sergott; M J Brown; D H Silberberg; R P Lisak
Journal:  J Neurol Sci       Date:  1984-06       Impact factor: 3.181

10.  Generation and biological properties of a monoclonal antibody to galactocerebroside.

Authors:  A Rostami; P A Eccleston; D H Silberberg; M Hirayama; R P Lisak; D E Pleasure; S M Phillips
Journal:  Brain Res       Date:  1984-04-30       Impact factor: 3.252

View more
  7 in total

1.  Suppression of the onset of myelination extends the permissive period for the functional repair of embryonic spinal cord.

Authors:  H S Keirstead; S J Hasan; G D Muir; J D Steeves
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 2.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

3.  Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice.

Authors:  Krishnakumar Menon; Yanghong Wu; Joel Haas; Shailendra K Sahu; Baoli Yang; Asgar Zaheer
Journal:  Neurosci Res       Date:  2007-02-22       Impact factor: 3.304

Review 4.  Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain.

Authors:  K E Schaecher; D C Shields; N L Banik
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

5.  Inhibition of myelin formation by HIV-1 gp120 in rat cerebral cortex culture.

Authors:  J Kimura-Kuroda; K Nagashima; K Yasui
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  Neurofascin as a novel target for autoantibody-mediated axonal injury.

Authors:  Emily K Mathey; Tobias Derfuss; Maria K Storch; Kieran R Williams; Kimberly Hales; David R Woolley; Abdulmonem Al-Hayani; Stephen N Davies; Matthew N Rasband; Tomas Olsson; Anja Moldenhauer; Sviataslau Velhin; Reinhard Hohlfeld; Edgar Meinl; Christopher Linington
Journal:  J Exp Med       Date:  2007-09-10       Impact factor: 14.307

7.  Neither B cells nor T cells are required for CNS demyelination in mice persistently infected with MHV-A59.

Authors:  A E Matthews; E Lavi; S R Weiss; Y Paterson
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.